Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATA-200 Gene Therapy in LGMDR5 (Phase I/II)
2023-506440-16-00Phase 2Authorised
- Sponsor
- Atamyo Therapeutics
- Start
- Feb 2024
- Modality
- Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label trial of GNT0007 in Limb-girdle muscular dystrophy type R5 (LGMDR5) (2 arms), sponsored by Atamyo Therapeutics. Primary endpoints: Incidence of adverse events, Incidence of clinically relevant abnormalities in vital signs and 5 more. Planned start Feb 2024; status: authorised.
02
Drugs
GNT0007
03
Conditions
Limb-girdle muscular dystrophy type R5 (LGMDR5)
Beyond the preview
Go deeper on 2023-506440-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506440-16-00.